NANOBIOANÁLISIS
NBA


Hospital Clinico Universitario de Valencia
Valencia, EspañaPublications in collaboration with researchers from Hospital Clinico Universitario de Valencia (6)
2024
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
HemaSphere, Vol. 8, Núm. 12
-
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial
Haematologica, Vol. 109, Núm. 12, pp. 4056-4066
2022
-
RICORS2040: The need for collaborative research in chronic kidney disease
Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387
-
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)
Leukemia and Lymphoma, Vol. 63, Núm. 14, pp. 3438-3447
2019
-
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807